Ken Page

Preclinical Pharmacology of AZD5363, an Inhibitor of AKT: Pharmacodynamics, Antitumor Activity, and Correlation of Monotherapy Activity with Genetic Background

Barry R. Davies, Hannah E. Greenwood, Phillippa Dudley et al. · Molecular Cancer Therapeutics · 2012 · 461 citations · Full text

Medicine, Oncology, Pharmacology +16

Discovery of 4-{4-[(3<i>R</i>)-3-Methylmorpholin-4-yl]-6-[1-(methylsulfonyl)cyclopropyl]pyrimidin-2-yl}-1<i>H</i>-indole (AZ20): A Potent and Selective Inhibitor of ATR Protein Kinase with Monotherapy in Vivo Antitumor Activity

Kevin M. Foote, Kevin Blades, Anna Cronin et al. · Journal of Medicinal Chemistry · 2013 · 215 citations · Full text

Medicine, Oncology, Pharmacology +13

In Vitro Approach to Assess the Potential for Risk of Idiosyncratic Adverse Reactions Caused by Candidate Drugs

Richard A. Thompson, Emre M. Isin, Yan Li et al. · Chemical Research in Toxicology · 2012 · 214 citations

Pharmacy, Pharmacology, Toxicology +17

Potent quinoxaline-Based inhibitors of PDGF receptor tyrosine kinase activity. Part 2: the synthesis and biological activities of RPR127963 an orally bioavailable inhibitor

Barbara Hanney, Alfred P. Spada, Glenda E. Bilder et al. · Bioorganic & Medicinal Chemistry Letters · 2003 · 152 citations · Full text

Medicine, Medicinal Chemistry, Pharmacology +16

Risk assessment and mitigation strategies for reactive metabolites in drug discovery and development

Richard A. Thompson, Emre M. Isin, Yan Li et al. · Chemico-Biological Interactions · 2010 · 102 citations

Pharmacy, Medicinal Chemistry, Pharmacology +17